S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY

MLA

Aaron T. Gerds, et al. “S167: Efficacy and Safety of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis: Results from the Ace-536-Mf-001 Study.” HemaSphere, vol. 7, Aug. 2023, p. e0882611. EBSCOhost, https://doi.org/10.1097/01.HS9.0000967580.08826.11.

APA

Aaron T. Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro Vannucchi, Rami S. Komrokji, Prithviraj Bose, Marina Kremyanskaya, Adam Mead, Jason Gotlib, Fabian Sanabria, Niloufar Marsousi, Ana Carolina Giuseppi, Huijing Jiang, Jeanne Palmer, Kelly Mccaul, Vincent Ribrag, Srdan Verstovsek, & Francesco Passamonti. (2023). S167: Efficacy and Safety of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis: Results from the Ace-536-Mf-001 Study. HemaSphere, 7, e0882611. https://doi.org/10.1097/01.HS9.0000967580.08826.11

Chicago

Aaron T. Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben Mesa, Alessandro Vannucchi, Rami S. Komrokji, Prithviraj Bose, et al. 2023. “S167: Efficacy and Safety of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis: Results from the Ace-536-Mf-001 Study.” HemaSphere 7 (August): e0882611. doi:10.1097/01.HS9.0000967580.08826.11.